Healthy children aged р2 years have hospitalization rates during influenza periods 12 times those of older children and comparable to rates in the elderly population. In 2003, killed influenza vaccines were "recommended" for children with high-risk conditions and were "encouraged" for children aged 6-23 months. Studies involving several thousand children show that split-virus vaccines are safe and immunogenic in healthy children aged у6 months and in high-risk children. In children aged р9 years, 2 doses of vaccine are required initially to achieve maximum protection. Studies of children aged 6 months to 15 years show vaccine efficacies of 31%-91% against influenza A and 45% against influenza B. Among children attending day care, a reduction in the rate of acute otitis media of 32%-36% was demonstrated. Studies suggest that use of killed vaccines among children is cost-saving. In conclusion, the data show that killed influenza vaccines in children are safe, immunogenic, effective, and potentially cost-saving.
Influenza, a major illness in the elderly population and for persons with underlying chronic conditions, kills up to 37,000 persons annually [1, 2] . Killed or inactivated influenza vaccines, which were first developed in the 1940s from viruses grown in embryonated chicken eggs, have evolved to highly purified, minimally reactogenic, standardized vaccines that are produced annually in millions of doses and updated annually to contain currently circulating strains of influenza A and B.
Recent epidemiological data show that influenza causes high rates of hospitalizations among children. Killed-virus influenza vaccines, which have been licensed for use in children aged у6 months for many decades, are largely unused for infants and children. Presently, there is an effort to expand the use of influenza vaccines among children [3] . At the 15-16 October children [5] . A report from Finland described influenza A and B virus infections that required hospital referral for 683 children [6] . Encephalitis, Guillain-Barré syndrome, myocarditis, and cardiac failure were complications. Acute encephalopathy with sequelae has been associated with influenza A virus infections in children [7] . Several other studies suggest that serious illness associated with influenza is not rare in children [8] [9] [10] [11] [12] .
These data demonstrate the impact of influenza on high-risk children and on children who are otherwise healthy, and they show that hospitalization rates for influenza in young children are equivalent to or greater than the rates for elderly persons [10, 11] . The authors of most of the studies above [9] [10] [11] and of other studies [13] have commented on the confounding effect of respiratory syncytial virus (RSV) infection, a frequent cause of lower respiratory illness-related hospitalization among infants and younger children [14] . With use of cultures for both influenza and RSV, a recent study from Hong Kong showed that, in certain years, influenza was a more frequent cause of hospitalization among children aged р2 years than was RSV infection [15] .
EVOLUTION OF NATIONAL RECOMMENDATIONS FOR USE OF INFLUENZA VACCINES IN CHILDREN
The first national recommendations for influenza vaccination, from US Surgeon General Leroy Burney in 1960 [16] , indicated that groups at high risk for death due to influenza should be immunized routinely each year, but the recommendations did not specifically mention children.
ACIP recommendations. Beginning with the 1960 national recommendations that included children in the category termed "high-risk persons," and through 2001, there were few substantive changes in national recommendations regarding indications for children. By contrast, recommendations regarding dose and type of influenza vaccine used in children have changed over time.
In 1966, the Public Health Service ACIP recommendations for the use of inactivated influenza vaccines were as follows: for children aged 110 years, a 1.0-mL dose; for children aged 6-10 years, a 0.5-mL dose; for infants and children aged 3 months through 5 years, a 0.1-0.2-mL dose followed by 2 additional doses, with the second dose given 1-2 weeks later and the third dose given 2 months later [17] .
The 1976 influenza vaccines (which included A/Swine [H1N1]) included both whole-virus and split-virus vaccines. The ACIP recommendations expressed a preference for the use of split-virus vaccines in both healthy and high-risk children, with no recommendations for children aged !3 years [18] .
By 1978, reports on the quantity of influenza vaccine antigens being used were expressed in micrograms of hemagglutinin (HA) per antigen [19] . From 1981 to the present, all influenza vaccines have had 15 mg of each HA antigen per 0.5 mL dose [20] . The dose recommended for children is two 0.25-mL doses for infants aged 6-35 months who are receiving vaccine for the first time and 0.5 mL for children aged у3 years, with children who received their first dose of vaccine before the age of 9 years requiring 2 doses. Beginning in 1984, the ACIP's annual influenza recommendations indicated that influenza vaccine should be offered to any persons who wished to reduce their chances of acquiring influenza infection [21] . Additional focus on healthy infants. After several decades of "recommending" influenza vaccines only for children with high-risk conditions, the 2002/2003 ACIP recommendations included healthy infants aged 6-23 months by "encouraging" the use of influenza vaccines in this age group [22] . At the recent 15-16 October 2003 meeting, the ACIP voted that, beginning in the fall of 2004, influenza vaccine would be "recommended" for children aged 6-23 months.
STUDIES OF THE SAFETY AND IMMUNOGENICITY OF KILLED-VIRUS INFLUENZA VACCINES
The following briefly summarizes 22 studies published since 1970 that report the use of inactivated (or "killed-virus") influenza vaccines in 14600 children. Table 1 summarizes selected  characteristics and table 2 summarizes the safety data from these studies. All vaccines used were grown in embryonated eggs. Before 1970, whole-virus vaccines were prepared by lowerspeed Sharples centrifugation. Subsequent whole-virus vaccines were prepared by high-speed, rate zonal centrifugation, which further removed egg impurities. Split-virus and subunit or subvirion vaccines became available in the 1970s. Vaccines from the older preparations, before split and subunit vaccines were available, were different from the current vaccines, and, therefore, immunogenicity, safety, and possibly efficacy data should not be extrapolated.
Studies reported in the 1970s. Phillips et al. [23] described a study involving 30 children who were subcutaneously given 1 dose of a zonal centrifuged monovalent whole-virus vaccine against type A influenza (Hong Kong variant). All children had serological conversion, and reactions were mild and local. Foy et al. [24] also studied type A Hong Kong whole-virus vaccine in school children aged 5-15 years. A monovalent type B influenza vaccine was used as a control. Rates of adverse reactions with the monovalent A vaccine were "encouragingly low," whereas the type B vaccine caused "an unacceptably high rate of systemic reactions." Schevill and Marks [25] evaluated zonal centrifuged, bivalent, whole-virus vaccine injected subcutane- ously in 155 children. Twenty-seven percent of children experienced local or systemic reactions, and 19% developed fever.
Phillips et al. [26] evaluated 2 doses of a bivalent split-virus vaccine given intramuscularly to 33 children aged 5-9 years. No local reactions were observed, and there were no systemic reactions within 48 h after administration attributable to the vaccine. After 1 dose, 94% of children developed a у4-fold increase in antibody titers to type A antigen, whereas 64% had such increases to the type B antigen. A booster dose did not significantly increase antibody titers.
Studies associated with Swine influenza of 1976. The threat of swine influenza in 1976 was the impetus for studies of influenza vaccines for children. Wright et al. [27] studied 4 different A/New Jersey/76 monovalent whole-or split-virus vaccines administered intramuscularly to 2326 healthy infants and children aged 6 months to 18 years. A single dose of splitvirus vaccine caused more mild, local erythema or tenderness than did placebo and was equivalent to placebo with regard to the frequency of systemic reactions. In contrast, after receipt of whole-virus vaccine, 6%-10% of recipients developed fever (temperature, у37.8ЊC) after 6 h. A booster dose of either vaccine did not elicit symptoms. Neither vaccine was satisfactorily antigenic after 1 dose. Sumaya and Brunell [28] studied 133 healthy children who were intramuscularly given either placebo, monovalent split-virus A/New Jersey/76 vaccine, or a whole-virus preparation. Reactions to both vaccines were minimal, and for both preparations, a booster dose was required to induce titers of у1:40.
Sumaya et al. [29] also studied bivalent A/New Jersey/76-A/ Victoria/75 vaccines, both split-and whole-virus, given intramuscularly to 46 children who also were receiving cancer chemotherapy. There were minimal adverse reactions after receiving 2 doses of either vaccine. With either vaccine, serological responses to 2 doses of the A/New Jersey/76 vaccine component were similar to those for healthy children.
Bell et al. [30] studied 79 asthmatic children aged 6-16 years.
Subjects were given bivalent, split-virus vaccine. Vaccinees were compared with unvaccinated control subjects with asthma for effects of vaccination on pulmonary function. Results showed no ill effects at 24 h; however, there was a transient decrease in peak expiratory flow rate at 48 h ( ) that coincided P ! .05 with the need for treatment with a bronchodilator drug (P ! ). Serological responses to the vaccine were comparable to .01 those found in healthy subjects without asthma.
Studies reported in the 1980s. Gross et al. [31] reported the antibody responses in 31 unprimed children and young adults with cystic fibrosis given a split-virus vaccine containing 43 mg of HA (compared with the current 15 mg of HA) from influenza A/USSR/77(H1N1), compared with those in 92 agematched subjects from an earlier trial, when vaccines contained doses of 10 mg and 4 mg of HA. Local and systemic side effects for each of the 3 vaccine groups were similar to those in a placebo group. There was a direct dose response observed to the influenza vaccines. Gross et al. [32] studied 2 different trivalent split-virus influenza vaccines in 76 children and young adults with moderate and severe asthma or cystic fibrosis. Vaccines contained 7 mg of HA for each strain of influenza virus, and 1 or 2 vaccine doses were given. Among the unprimed (seronegative) individuals, after 1 dose of vaccine, the geometric mean responses to both strains of influenza A were 100, whereas the same responses to the B component were 32. There were no febrile reactions within 24 h after administration, and 6 to 7 recipients from each vaccine group had local arm tenderness.
Miles et al. [33] studied 220 healthy children aged 5-12 years who were given trivalent split-virus vaccines or a whole-virus vaccine subcutaneously in 2 doses. Whole-virus vaccine caused fever more frequently than did the split-virus vaccines, but local-reaction rates were similar for both vaccines. Serological results also were similar. Miles et al. [34] also studied the responses of 61 children to a more highly purified trivalent aqueous subunit-virus vaccine containing only HA and neuraminidase, compared with a trivalent, adsorbed, subunit-virus vaccine. Vaccines were equally immunogenic and caused few reactions.
Gross et al. [35] reported on a study in which 80 subjects with cystic fibrosis (age, 3-30 years) were given, in 2 doses, 1 of 2 trivalent split-virus vaccines containing 7 mg of each antigen and another trivalent vaccine with 60 mg of the B/Singapore component. The B/Singapore vaccine was no more reactogenic and induced significantly higher titers than did the other vaccine ( . P ! .05) Bernstein et al. [36] administered 2 doses of a whole-virus or split-virus vaccine to 168 subjects (age, 6 months to 22 years) in a partially blinded study conducted over 2 years. Approximately 15% of subjects had cystic fibrosis, ∼10% had heart disease, ∼65% were healthy infants and young adults, and ∼10% had another chronic illness. For each vaccine, the first dose was a monovalent vaccine containing 7 mg/0.5 mL of A/ USSR/77(H1N1). The second vaccine dose, which was given 1 month later, contained A/USSR/77(H1N1), A/Texas/77(H3N2), and B/Hong Kong/72 (each at 7 mg/0.5 mL). Subjects aged !3 years received 0.25 mL per dose, and older subjects received 0.5 mL per dose. Results showed similar reactions for wholevirus and split-virus vaccines after each dose, except for subjects aged 6-36 months who were given the whole-virus vaccine, who had more instances of fever after receipt of both doses than did their counterparts who received split-virus vaccine. No subjects had temperatures of у39.4ЊC. Serological testing showed that receipt of the second dose was followed by increased titers to all 3 antigens. Receipt of 1 dose of either vaccine induced hemagglutination inhibition (HAI) antibody titers of у20 to the H3N2 component in 190% of subjects.
Studies reported in the 1990s. Ghirga et al. [37] studied 95 infants and children with moderate to severe asthma who were given 1 or 2 doses of trivalent subunit vaccine. Three infants exhibited some restriction of limb movement, but none of the children experienced fever, and no child had asthma worsening. Groothuis et al. [38] studied 113 children with bronchopulmonary dysplasia or congenital heart disease; 62 were aged 3-5 months, and 51 were aged 6-18 months. The vaccine was a trivalent split-virus vaccine containing 15 mg of each component in a 0.5-mL dose. Doses of 0.25 mL were given 4-6 weeks apart. Of the 3-5-month-old children, 14% experienced reactions, all of which were mild. Of the older children, 6% had reactions, and all but 1 of the reactions were mild. One child with a fever (temperature, 39.53ЊC) had a seizure after receiving only 1 dose of vaccine. After 3 years of follow-up, this child remained healthy. In general, seroconversion (i.e., a 4-fold increase in titer) required 2 doses of vaccine. Brydak et al. [39] reported data on 6 infants aged 8-21 months who had bronchopulmonary dysplasia. After receiving two 0.25-mL intramuscular doses of trivalent split-virus vaccine, the mean fold increases in geometric-mean HAI titers ranged from 10.5 to 21.1.
Mack et al. [40] studied 39 children who had undergone liver transplantation. Thirty-seven children received 1 dose and 2 children received 2 doses of trivalent whole-or split-virus influenza vaccine. A protective titer (у1:40) was achieved by 56%-67% of the children, depending on the antigenic strain, after receipt of only 1 dose. The second dose provided a 2%-5% increase in the percentage of children protected. During a 6-month follow-up period, there was no increase in acute allograft rejections in immunized patients, compared with 137 other pediatric transplant recipients.
Lina et al. [41] reported data on 42 healthy children aged 8-10 years who were given 1 dose of trivalent split-virus influenza vaccine. Forty percent of the subjects experienced у1 local reaction, pain, or erythema, and 12% experienced у1 systemic reaction, malaise, or headache. Eighty-three percent to 100% of the children developed protective titers (HAI, у1 :40) to all 3 strains in the vaccine.
Gonzalez et al. [42] studied 67 healthy infants aged !3 years (mean age, 20.8 months) who were given two 0.25-mL doses of trivalent split-virus influenza vaccine. Nine percent of infants had у1 local reaction, and 28% had у1 systemic reaction. A total of 81%-93% developed protective titers (HAI, у1:40) to all 3 vaccine strains.
Schmitt-Grohé et al. [43] reported a study involving 83 healthy infants and children (age, 6 months to 12 years) who were given up to 2 doses of trivalent split-virus influenza vaccine. Forty percent of children reported mild-to-moderate local reactions, and 96%-100% developed seroprotection (HAI, у1:40).
Studies reported in the 2000s. Safety of killed-virus influenza vaccine for asthmatic persons was studied in a 19-center, randomized, double-blind, placebo-controlled trial [44] . Participants ranged in ages from 3 to 64 years and included 713 children (mean age, 9.4 years). Subjects received either trivalent split-virus vaccine or a sterile saline placebo. Results showed that the frequency of exacerbations of asthma within 3 and 14 days after injection of the vaccine or the placebo was not significantly different (28.8% and 27.7% for vaccine and placebo recipients, respectively). The conclusion was that inactivated influenza vaccine is safe for children with asthma.
In summary, 22 studies reported since 1970 that have involved healthy children and, to a limited extent, children with high-risk conditions have showed that killed-virus influenza vaccines have evolved over the years. In children, split-virus and subunit vaccines have consistently proved to elicit fewer reactions than do whole-virus vaccines. Overall, the split-virus influenza vaccines were shown to be safe and immunogenic for healthy children. Two doses of vaccine are required for younger children to achieve both maximum seroconversion and seroprotective levels of antibodies. Limited studies involving children with high-risk conditions have also demonstrated safety and immunogenicity. Table 3 summarizes studies involving children that have evaluated the efficacy of killed-virus influenza vaccines.
STUDIES OF THE EFFICACY OF KILLED-VIRUS INFLUENZA VACCINES
Efficacy in asthmatic individuals. In 1994, Sugaya et al. [45] reported a prospective, nonrandomized, controlled trial of influenza vaccine involving 137 children with moderate-to-severe asthma (mean age, 7.0 years; range, 2-14 years). Eighty-five children received trivalent split-virus influenza vaccine in 2 doses given 2-4 weeks apart, and 52 remained unvaccinated. Influenza was defined as a febrile episode with increases in antibody or viral isolation. The influenza season that followed had both influenza A and influenza B disease. The rate of protection against influenza A disease from the vaccine was 67.5% ( ), and P ! .01 it was 43.7% against influenza B disease (P ! .01).
Efficacy against serologically diagnosed influenza. Hurwitz et al. [46] reported on a randomized, partially blinded, controlled study of the efficacy of vaccination with split-virus influenza vaccine for preventing serologically diagnosed influenza. Children (age, 24-60 months) were from 10 day care centers. Estimates of vaccine efficacy against infection were based on the incidence of serologically confirmed influenza infections among those who received influenza vaccine, compared with control subjects. One hundred fifty of 748 eligible children were enrolled. The influenza season was identified through community viral surveillance. Results showed an outbreak of both influenza B and influenza A(H3N2). The vaccine efficacies in preventing serologically proven virus infection were 0.45 (95% CI, Ϫ0.02 to 0.69) for influenza B and 0.31 (95% CI, Ϫ0.95 to 0.73) for influenza A(H3N2).
Efficacy against febrile respiratory illness in preschool children. Colombo et al. [47] reported a randomized trial involving 344 healthy children aged 1-6 years in Sardinia, Italy. Trivalent split-virus influenza vaccine in 2 doses was given to 177 healthy preschool children; 167 children received no vaccine. The end points were influenza-like episodes with fever and cough or sore throat lasting for у72 h. Episodes of illness occurred in 63 unvaccinated children (37.7%), compared with 22 vaccinated children (12.4%), for a reduction of 67% (95% CI, 59%-74%).
Randomized, controlled trial involving children aged !16 years. Neuzil et al. [48] reported findings of a reanalysis of data from a randomized, controlled trial conducted during 1985-1990 of both live, cold-adapted influenza-virus vaccines and inactivated split-virus influenza vaccines for the prevention of influenza A. A subset of 635 children aged !16 years at the time of participation had received trivalent inactivated influenza vaccine, and 574 control subjects had received monovalent inactivated influenza B vaccine. On the basis of culture-positive influenza in control subjects given the monovalent influenza B vaccines, during years when influenza A(H1N1) was prevalent, the efficacy rate for trivalent inactivated influenza vaccines was 91% (95% CI, 64%-98%). During years when influenza A(H3N2) was prevalent, the efficacy of trivalent inactivated influenza vaccines was 77% (95% CI, 20%-93%). On the basis of postvaccination-to-springtime seroconversions, trivalent inactivated vaccines had efficacies of 67% (95% CI, 51%-78%) and 65% (95% CI, 39%-84%) at reducing seroconversions to A(H1N1) and A(H3N2) serotypes, respectively. Double-blind, randomized, placebo-controlled trial involving children aged 6-24 months against culture-proven influenza. During 2 influenza seasons, Hoberman et al. [49] con- ducted a double-blind, randomized, saline-placebo controlled trial of 2 doses of trivalent split-virus inactivated influenza vaccine involving infants aged 6-24 months, 51% of whom were aged 6-12 months. The main study objective was to evaluate vaccine efficacy against acute otitis media, but a secondary study objective was to evaluate efficacy against culture-proven influenza. In the first year, a cohort of 411 children was enrolled, and, in the second year, a new cohort of 375 children was enrolled. Compared with placebo, influenza vaccine did not significantly reduce the proportion of children who had у1 episode of acute otitis media during the ensuing respiratory season (for the first cohort, 49.2% vs. 52.2%, respectively; for the second cohort, 55.8% vs. 48.3%, respectively). However, the efficacy of the vaccine against culture-proven influenza was 66% (95% CI, 34%-82%) in the first year, when the influenza attack rate was 9%, and the efficacy was Ϫ7% (95% CI, Ϫ247% to 67%) in year 2, when the attack rate for influenza was only 3%. In both years, influenza vaccine induced seroconversion (titer, у1:40) to each of the 3 vaccine strains in у90% of recipients. In each year, the vaccine was well tolerated.
Other controlled trials involving day care centers evaluating efficacy against otitis media. There have been 2 controlled trials of inactivated influenza vaccines involving older children who attended day care centers, and each evaluated efficacy against otitis media. Heikkinen et al. [50] reported a trial involving 187 children aged 1-3 years (mean age, 2.2 years) who were given trivalent split-virus influenza vaccine and 187 control children who remained unvaccinated. During the 6-week study period, influenza A infection was diagnosed in 5 vaccinees (3%) and in 29 control subjects (16%); vaccine efficacy was 83% (
). Acute otitis media was diagnosed in 36 (34%) P ! .0001 of 105 cases of respiratory tract infection in the vaccinated subjects, compared with 60 (53%) of the 114 cases in the control group, for a 36% reduction ( ). Clements et al.
[51] P ! .02 reported a prospective cohort study of split-virus influenza vaccination of 186 children aged 6-30 months (mean age, 20 months). Influenza vaccinees had an overall reduction in the rate of otitis media of 32% ( ). P p .02 Community-based study of the effectiveness of immunizing school children. In a study by Monto et al. [52] conducted in 1968, whole-virus influenza vaccine containing A/Aichi/2/ 68, related to the newly emerging A/Hong Kong (H3N2) virus, was given in to 3159 school children in elementary, junior high, and high schools (85% of the total enrollment) in Tecumseh, Michigan. A very limited amount of this vaccine was given to high-risk persons in the community. For a control site, 2 nearby communities, Adrian and Flint, had customary immunization with a non-Hong Kong strain containing killed-virus influenza vaccine. Family surveillance and school absenteeism were used to monitor for respiratory illnesses in all sites. Results of immunization demonstrated that Tecumseh school children responded to the vaccine, with 95% attaining у4-fold increases in antibody. Surveillance showed an outbreak of A/Hong Kong in both sites. With a defined 8% epidemic threshold for school absenteeism based on data collected from the 7 preceding years, the control site of Adrian exceeded the threshold at 14%, whereas Tecumseh never exceeded the 8% threshold. The attack rate in Adrian for the entire population, based on the 10-week influenza outbreak, was 3 times greater than for Tecumseh. Age-specific attack rates were lower in Tecumseh than in Adrian for all age groups. The conclusion was that vaccination of school children had prevented illness and had prevented the spread of illness into the community.
National experience with immunizing school children. Reichert et al. [53] described a national experience in Japan with immunizing children. Beginning in the 1970s and continuing into the mid-1980s, there was a national policy to immunize all school-age children with killed-virus influenza vaccines that was reversed in 1994. The authors reviewed national statistics for all-cause mortality and for mortality due to pneumonia and influenza, both in Japan and the United States, for the years 1949-1998. The review showed that the all-cause mortality rate in both countries had winter peaks, with the peaks being somewhat higher in Japan. Comparison of rates of mortality due to pneumonia and influenza between Japan and the United States showed similar patterns of peaks; however, Japanese peaks were much higher than those in the United States before 1966, were similar during the period of 1966-1992, and returned to higher levels in Japan after 1994. During the program for immunizing school children, mortality due to pneumonia and influenza decreased by 10,000-12,000 deaths per year, and the all-cause mortality rate decreased by 37,000-49,000 deaths per year.
In summary, there have been only a limited number of reports (9 reports described here) on the efficacy of killed-virus influenza vaccines in children. Efficacy in preventing influenza has been reported to be as high as 91% against influenza A (range, 31%-91%) and 45% against influenza B in those years when the influenza attack rates were increased sufficiently to evaluate efficacy. Although vaccinated infants aged 6-24 months were protected against culture-positive influenza illness, in this age group, there was no demonstrable efficacy against otitis media in one study. In contrast, 2 other studies involving older-age children who attended day care center and who were given killed-virus influenza vaccine showed a 32%-36% reduction in the occurrence of otitis media during the influenza season. Giving killed-virus influenza vaccines to school-aged children was shown to reduce the impact of influenza in older, unvaccinated adults in 2 very large studies.
RECENT ASSESSMENTS OF INFLUENZA VACCINE COVERAGE IN CHILDREN
Despite the recommendations that children with high-risk conditions be given influenza vaccine annually, indications are that the rate of vaccine coverage in these children is very low [22] . Coverage has ranged from 25% in one study [54] to as low as 9% in another study [55] . In an attempt to increase this coverage, a reminder-recall system was used in a pediatric clinic [56] , resulting in an increase from 5% to 32% in the vaccination rate for children with asthma and reactive airway disease. These low percentages of influenza vaccine coverage in children are in sharp contrast with 2001 figures of national coverage for routine childhood immunizations, which were as much as 78% for the combined series of recommended vaccines [57] . Coverage in children also lags far behind the coverage for persons aged у65 years, which was 66% in 1999 [22] .
ECONOMICS OF KILLED-VIRUS INFLUENZA VACCINES
Data from several US economic studies of influenza vaccination of persons aged у65 years report overall societal cost savings and substantial reductions in morbidity and mortality [58] [59] [60] . Reports also describe the cost-effectiveness of vaccinating children. Dayan et al. [61] studied the cost-effectiveness of influenza vaccination in high-risk infants and children aged 6 months to 15 years in Argentina. Assuming an influenza incidence of 25% and vaccine efficacy of 70%, vaccination of all high-risk children would be cost-saving for society, with a net savings of US$10.04 per vaccinated child. Cohen and Nettleman [62] estimated the economic impact of influenza vaccination in preschool children. Vaccination that was available during flexible hours resulted in net cost savings of US$21.28. White et al. [63] evaluated the potential cost savings attributable to influenza vaccination of school-aged children. Vaccination resulted in a net savings per vaccinated child of US$4 for individual-initiated vaccination and of US$35 for group-based vaccination. Muenning and Khan [64] evaluated the cost-effectiveness of influenza vaccination compared with treatment of influenza in healthy adolescents and adults aged 15-65 years. Vaccination saved approximately US$25 per person while resulting in a net gain of 3.2 quality-adjusted hours, relative to providing treatment with an orally taken neuraminidase inhibitor.
IMPLEMENTATION OF A POLICY OF VACCINATING INFANTS
A major impediment to the use of influenza vaccine in infants is implementing a policy that would require additional visits to receive the 1-2 doses of vaccine needed each year. A technical report by the American Academy of Pediatrics [65] indicated that it would be a challenge for pediatricians to accomplish this in the brief time period in the fall when vaccine becomes available.
Szilagy et al. [66] evaluated the amount of time spent by primary care providers on pediatric influenza vaccine visits and concluded that "it may be necessary to implement vaccination clinics or sessions in which large numbers of children are scheduled for influenza vaccinations at times when adequate rooms and dedicated nursing staff are available" (p. 195).
LIVE ATTENUATED INFLUENZA VACCINES FOR CHILDREN
Live attenuated influenza vaccine has been recently licensed for use in the United States. Live attenuated influenza vaccines contain viruses still capable of replication and are administered by a nasal sprayer, whereas inactivated influenza vaccines contain killed viruses and are administered by intramuscular injection. Live attenuated influenza vaccine is approved for use only among healthy persons aged 5-49 years, whereas inactivated influenza vaccine is approved for persons aged у6 months, including those who are healthy and those with chronic medical conditions [67] .
CONCLUSIONS
Killed-virus influenza vaccines have improved during the decades since the 1960s. Current vaccines are highly purified splitvirus vaccines that have been studied extensively in children aged у6 months. These studies have shown that killed-virus influenza vaccines are safe and immunogenic, cause mainly local reactions, and elicit protective levels of antibodies against the vaccine strains. In years with sufficient disease rates for study, killed-virus vaccines have shown efficacy for the prevention of influenza ranging from 31% to 91% in healthy children (in 5 separate studies) and in subjects with asthma (in 1 study) ranging in age from 6 months to 15 years. In 2 separate studies, killed-virus vaccines prevented 32%-36% of cases of acute otitis media during the influenza season in children aged 1-3 years who attended day care centers. Economic analyses conclude that vaccinating children against influenza is costsaving. On the basis of this review, future studies with killedvirus influenza vaccines might include additional studies of their efficacy against influenza virus infection and the effect on hospitalization due to influenza-associated diseases, such as pneumonia, croup, and other complications in children.
